Live Respiratory Syncytial Virus Vaccine D46/cp/ΔM2-2 Is Overattenuated in RSV-Seronegative Children
- 29 July 2026
- journal article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (8)
Abstract
The intranasal respiratory syncytial virus (RSV) vaccine D46/cp/ΔM2-2 is attenuated by deletion of the RSV RNA synthesis factor M2-2 and 5 cold-passage amino acid mutations. D46/cp/ΔM2-2 was safe but overattenuated in 12- to 59-month-old RSV-seropositive children (dose: 106 plaque-forming units [PFU]) and 6- to 24-month-old RSV-seronegative children (dose: 105 PFU). Clinical Trials Registration. ClinicalTrials.gov Number . NCT02601612.Keywords
Funding Information
- National Institutes of Health (75N93030F0001)
- U.S. Department of Health and Human Services
This publication has 12 references indexed in Scilit:
- Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative ChildrenThe Journal of Infectious Diseases, 2022
- Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysisThe Lancet, 2022
- Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in ChildrenThe Journal of Infectious Diseases, 2020
- Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in ChildrenThe Journal of Infectious Diseases, 2020
- Live-Attenuated Respiratory Syncytial Virus Vaccine With Deletion of RNA Synthesis Regulatory Protein M2-2 and Cold Passage Mutations Is OverattenuatedOpen Forum Infectious Diseases, 2019
- Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and ChildrenThe Journal of Infectious Diseases, 2018
- Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in ChildrenThe Journal of Infectious Diseases, 2018
- A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in childrenScience Translational Medicine, 2015
- The M2–2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcriptionProceedings of the National Academy of Sciences, 1999
- Low-Temperature-Grown RS Virus in Adult VolunteersJAMA, 1968